Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The multi-factorial nature of clinical multidrug resistance in cancer
Yehuda G. Assaraf, Anamaria Brozović, Ana Cristina Gonçalves, et al.
Drug Resistance Updates (2019) Vol. 46, pp. 100645-100645
Closed Access | Times Cited: 438

Showing 1-25 of 438 citing articles:

Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
Nuray Erin, Jelena Grahovac, Anamaria Brozović, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100715-100715
Open Access | Times Cited: 389
Extracellular vesicles as tools and targets in therapy for diseases
Mudasir A. Kumar, Sadaf Khursheed Baba, Hana Q. Sadida, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 291
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Silpa Narayanan, Chao‐Yun Cai, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2019) Vol. 48, pp. 100663-100663
Closed Access | Times Cited: 254
Anticancer drug resistance: An update and perspective
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Drug Resistance Updates (2021) Vol. 59, pp. 100796-100796
Open Access | Times Cited: 251
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Sabrina Dallavalle, Vladimir Dobričić, Loretta Lazzarato, et al.
Drug Resistance Updates (2020) Vol. 50, pp. 100682-100682
Open Access | Times Cited: 241
Apoptosis Deregulation and the Development of Cancer Multi-Drug Resistance
Christiana M. Neophytou, Ioannis P. Trougakos, Nuray Erin, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4363-4363
Open Access | Times Cited: 240
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Luciana Mosca, Andrea Ilari, Francesco Fazi, et al.
Drug Resistance Updates (2021) Vol. 54, pp. 100742-100742
Closed Access | Times Cited: 228
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Marilyne Labrie, Joan S. Brugge, Gordon B. Mills, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 6, pp. 323-339
Open Access | Times Cited: 223
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Jinyun Dong, Zuodong Qin, Weidong Zhang, et al.
Drug Resistance Updates (2020) Vol. 49, pp. 100681-100681
Closed Access | Times Cited: 209
Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)
Hang Zhang, Hai‐Wei Xu, Charles R. Ashby, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 1, pp. 525-555
Closed Access | Times Cited: 208
The role of alternative splicing in cancer: From oncogenesis to drug resistance
Rocco Sciarrillo, Anna Wojtuszkiewicz, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100728-100728
Open Access | Times Cited: 197
Multiple Myeloma: Available Therapies and Causes of Drug Resistance
Vanessa Carla Monteiro Pinto, Rui Bergantim, Hugo R. Caires, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 407-407
Open Access | Times Cited: 190
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez-Ruíz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 174
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Elisabeth Pérez-Ruíz, Ignacio Melero, Joanna Kopecka, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100718-100718
Open Access | Times Cited: 162
Adaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Peijie Wu, Wei Gao, Miao Su, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 159
Molecular and cellular paradigms of multidrug resistance in cancer
Foram U. Vaidya, Abu Sufiyan Chhipa, Vinita Mishra, et al.
Cancer Reports (2020) Vol. 5, Iss. 12
Open Access | Times Cited: 157
Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment
Yang Zhang, Yanni Lou, Jingbin Wang, et al.
Frontiers in Immunology (2021) Vol. 11
Open Access | Times Cited: 156
Therapeutic strategies to overcome taxane resistance in cancer
Tuyelee Das, Uttpal Anand, Swaroop Kumar Pandey, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100754-100754
Closed Access | Times Cited: 156
3D Cell Culture Models as Recapitulators of the Tumor Microenvironment for the Screening of Anti-Cancer Drugs
Mélanie A. G. Barbosa, Cristina P. R. Xavier, Rúben F. Pereira, et al.
Cancers (2021) Vol. 14, Iss. 1, pp. 190-190
Open Access | Times Cited: 151
Cancer drug resistance induced by EMT: novel therapeutic strategies
Javier De Las Rivas, Anamaria Brozović, Sivan Izraely, et al.
Archives of Toxicology (2021) Vol. 95, Iss. 7, pp. 2279-2297
Open Access | Times Cited: 147
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang Yang, Shuo Li, Yujiao Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 143
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification
Bowen Li, Jingwen Jiang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100720-100720
Closed Access | Times Cited: 141
Novel nanomedicines to overcome cancer multidrug resistance
Zhenwei Su, Shaowei Dong, Shan‐Chao Zhao, et al.
Drug Resistance Updates (2021) Vol. 58, pp. 100777-100777
Closed Access | Times Cited: 137
Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
Sepideh Mirzaei, Mohammad Gholami, Farid Hashemi, et al.
Drug Discovery Today (2021) Vol. 27, Iss. 2, pp. 436-455
Open Access | Times Cited: 134
A Critical Review of the Use of Surfactant-Coated Nanoparticles in Nanomedicine and Food Nanotechnology
Taiki Miyazawa, Mayuko Itaya, Gregor Carpentero Burdeos, et al.
International Journal of Nanomedicine (2021) Vol. Volume 16, pp. 3937-3999
Open Access | Times Cited: 131
Page 1 - Next Page

Scroll to top